

44. Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β -cyclodextrin in haematological patients with renal impairment. *Mycoses*. 2016;59(10):644-651.
45. Lilly CM, Welch VL, Mayer T, et al. Evaluation of intravenous voriconazole in patients with compromised renal function. *BMC Infect Dis*. 2013;13:14.
46. Oude Lashof AML, Sobel JD, Ruhnke M, et al. Safety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency and Candidemia. *Antimicrob Agents Chemother*. 2012;56(6):3133-3137.
47. Neofytos D, Lombardi LR, Shields RK, et al. Administration of Voriconazole in Patients With Renal Dysfunction. *Clinical Infectious Diseases*. 2012;54(7):913-921.
48. Yasu T, Konuma T, Kuroda S, et al. Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients. *Antimicrob Agents Chemother*. 2018;62(9):e00507-18.
49. Food and Drug Administration [on-line]. ERAXIS® (anidulafungin) for injection, for intravenous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021632027_S029lbl.pdf.
50. Food and Drug Administration [on-line]. CELLCEPT Intravenous (mycophenolate mofetil) for injection, for intravenous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050722s049s051,050723s049s051,050758s047s049lbl.pdf.